Posted by Michael Wonder on 12 Jul 2018
New Zealand’s medicines waiting list: international disgrace for patient equity
12 July 2018 - The medicines waiting list grows to over 100 priority medicines that wait to be publicly funded by PHARMAC.
All medicines on this list have been recommended to benefit patients and New Zealand’s healthcare system by PHARMAC’s own technical advisory board.
The medicines waiting list has grown from 86 medicines in 2017 to 103 medicines in 2018.
“It shows that PHARMAC are ignoring recommendations from their own specialist advisory board. New Zealand patients are missing out on over 100 medicines that could provide better treatment for cancer, diabetes, arthritis and many other chronic diseases, ” says Dr Graeme Jarvis, General Manager of Medicines New Zealand.
